InflaRx’s Hold Rating Amid Trial Delays and Uncertain Clinical Data

LifeSci Capital analyst Sam Slutsky has maintained their neutral stance on IFRX stock, giving a Hold rating yesterday.

Sam Slutsky has given his Hold rating due to a combination of factors related to InflaRx’s recent developments and future prospects. The company has reported a delay in the data readout for its Phase 2a trial of INF904, which is now expected between the end of September and early November. This delay is attributed to slower enrollment rates, which could impact the timeline for subsequent studies and potential market entry.
Additionally, while there have been positive updates from their Chinese partner, Staidson BioPharmaceuticals, regarding the efficacy of a related treatment in AAV patients, the overall uncertainty surrounding the clinical data for INF904 in CSU and HS remains a concern. The Hold rating reflects a cautious stance, as the outcomes of these trials are crucial for assessing the drug’s potential and the company’s future performance.

In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.00 price target.